PT  - JOURNAL ARTICLE
AU  - Kopajtich, Robert
AU  - Smirnov, Dmitrii
AU  - Stenton, Sarah L.
AU  - Loipfinger, Stefan
AU  - Meng, Chen
AU  - Scheller, Ines F.
AU  - Freisinger, Peter
AU  - Baski, Robert
AU  - Berutti, Riccardo
AU  - Behr, Jürgen
AU  - Bucher, Martina
AU  - Distelmaier, Felix
AU  - Graf, Elisabeth
AU  - Gusic, Mirjana
AU  - Hempel, Maja
AU  - Kulterer, Lea
AU  - Mayr, Johannes
AU  - Meitinger, Thomas
AU  - Mertes, Christian
AU  - Metodiev, Metodi D.
AU  - Nadel, Agnieszka
AU  - Nasca, Alessia
AU  - Ohtake, Akira
AU  - Okazaki, Yasushi
AU  - Olsen, Rikke
AU  - Piekutowska-Abramczuk, Dorota
AU  - Rötig, Agnès
AU  - Santer, René
AU  - Schindler, Detlev
AU  - Slama, Abdelhamid
AU  - Staufner, Christian
AU  - Strom, Tim
AU  - Verloo, Patrick
AU  - von Kleist-Retzow, Jürgen-Christoph
AU  - Wortmann, Saskia B.
AU  - Yépez, Vicente A.
AU  - Lamperti, Costanza
AU  - Ghezzi, Daniele
AU  - Murayama, Kei
AU  - Ludwig, Christina
AU  - Gagneur, Julien
AU  - Prokisch, Holger
TI  - Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders
AID  - 10.1101/2021.03.09.21253187
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.09.21253187
4099  - http://medrxiv.org/content/early/2021/07/03/2021.03.09.21253187.short
4100  - http://medrxiv.org/content/early/2021/07/03/2021.03.09.21253187.full
AB  - By lack of functional evidence, genome-based diagnostic rates cap at approximately 50% across diverse Mendelian diseases. Here, we demonstrate the effectiveness of combining genomics, transcriptomics, and, for the first time, proteomics and phenotypic descriptors, in a systematic diagnostic approach to discover the genetic cause of mitochondrial diseases. On fibroblast cell lines from 145 individuals, tandem mass tag labelled proteomics detected approximately 8,000 proteins per sample and covered over 50% of all Mendelian disease-associated genes. Aberrant protein expression analysis allowed the validation of candidate protein-destabilising variants, in addition to providing independent complementary functional evidence to variants leading to aberrant RNA expression. Overall, our integrative computational workflow led to genetic resolution for 22% of 121 genetically unsolved whole exome or whole genome negative cases and to the discovery of two novel disease genes. With increasing democratization of high-throughput omics assays, our approach and code provide a blueprint for implementing multi-omics based Mendelian disease diagnostics in routine clinical practice.Competing Interest StatementA.O. declares a consigned research fund (SBI Pharmaceuticals Co., Ltd.). All other authors declare no conflict of interest.Funding StatementThis study was supported by a German Federal Ministry of Education and Research (BMBF, Bonn, Germany) grant to the German Network for Mitochondrial Disorders (mitoNET, 01GM1906D), the German BMBF and Horizon2020 through the E-Rare project GENOMIT (01GM1920A), the ERA PerMed project PerMiM (01KU2016A), the German BMBF through the e:Med Networking fonds AbCD-Net (FKZ 01ZX1706A), the German Research Foundation/Deutsche Forschungsgemeinschaft (DI 1731/2-2), the AFM-Telethon grant (#19876), the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development, AMED (JP19ek0109273, JP20ek0109468, JP20kk0305015, JP20ek0109485), a CMHI grant (S145/16), a PMU-FFF grant (A-20/01/040-WOS), the Pierfranco and Luisa Mariani Foundation (CM23), and the Italian Ministry of Health (GR-2016-02361494, GR-2016-02361241).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All individuals included in the study or their legal guardians provided written informed consent before evaluation, in agreement with the Declaration of Helsinki and approved by the ethical committees of the centres participating in this study, where biological samples were obtained. All studies were completed according to local approval of the ethical committee of the Technical University of Munich.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe proteomic raw data and MaxQuant search files have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository and can be accessed using the dataset identifier PXD022803. Code to reproduce the analysis is available via GitHub at github.com/prokischlab/omicsDiagnostics/. https://github.com/prokischlab/omicsDiagnostics/